Contributions
Type: Publication Only
Background
Introduction. Since the first description by Paul Arliam acquired aplastic anemia (AA) over 100 years ago, but today this disease remains in the spotlight hematologists and physicians in adjacent fields. AA - a serious disease of the blood system, resulting from damage to the stem cells (precursors of all blood cells), resulting in a profound inhibition of normal hematopoiesis with the development of pancytopenia. One of the main clinical manifestations is hemorrhagic syndrome caused by thrombocytopenia. Moreover, the clinically significant hemorrhagic syndrome is observed usually only with severe thrombocytopenia. In connection with this, is of great interest the study of the compensating functions of the system of hemostasis in AA – patients.
Aims
The search for diagnostic markers hypercoagulation status in patients with AA.
Methods
The research material was venous blood 25 patients (17 men and 8 women, mean age 38±0,5), with a diagnosis of aplastic anemia'. Plasma level of hemostasis was evaluated in the following coagulation tests: activated partial thromboplastin time (APTT), prothrombin time Quick (PT), thrombin time (TT), the concentration of fibrinogen (Fg), the activity of the factor VIII activity of antithrombin (AT). The control group consisted of 40 clinically healthy men and women of similar age.
Results
Compared to the normal performance of screening tests (APTT, PV, TV, FG) in 18 (72%) of 25 patients reported a significant increase in the activity of factor VIII, which is usually regarded as an indicator hypercoagulation state of hemostasis (189,8%±96,5% against normal value 119,0%±30.5%, p < 0,001). However, in 8 (44%) of 18 patients with elevated factor VIII revealed reduced levels of antithrombin, which amounted to 68% (fluctuations from 74% to 62%). However, clinical manifestations hypercoagulation syndrome (thrombosis and thromboembolism) single patient not were observed.
Summary
Thus, in patients with AA showed increased activity of factor VIII and decreased levels of anti-thrombin. Whether these indicators markers hypercoagulation state, or is it a manifestation of compensatory functions, which prevent severe hemorrhagic complications in this category of patients. Research in this direction continues.
Keyword(s): Anemia, Hypercoagulation, Thrombocytopenia
Type: Publication Only
Background
Introduction. Since the first description by Paul Arliam acquired aplastic anemia (AA) over 100 years ago, but today this disease remains in the spotlight hematologists and physicians in adjacent fields. AA - a serious disease of the blood system, resulting from damage to the stem cells (precursors of all blood cells), resulting in a profound inhibition of normal hematopoiesis with the development of pancytopenia. One of the main clinical manifestations is hemorrhagic syndrome caused by thrombocytopenia. Moreover, the clinically significant hemorrhagic syndrome is observed usually only with severe thrombocytopenia. In connection with this, is of great interest the study of the compensating functions of the system of hemostasis in AA – patients.
Aims
The search for diagnostic markers hypercoagulation status in patients with AA.
Methods
The research material was venous blood 25 patients (17 men and 8 women, mean age 38±0,5), with a diagnosis of aplastic anemia'. Plasma level of hemostasis was evaluated in the following coagulation tests: activated partial thromboplastin time (APTT), prothrombin time Quick (PT), thrombin time (TT), the concentration of fibrinogen (Fg), the activity of the factor VIII activity of antithrombin (AT). The control group consisted of 40 clinically healthy men and women of similar age.
Results
Compared to the normal performance of screening tests (APTT, PV, TV, FG) in 18 (72%) of 25 patients reported a significant increase in the activity of factor VIII, which is usually regarded as an indicator hypercoagulation state of hemostasis (189,8%±96,5% against normal value 119,0%±30.5%, p < 0,001). However, in 8 (44%) of 18 patients with elevated factor VIII revealed reduced levels of antithrombin, which amounted to 68% (fluctuations from 74% to 62%). However, clinical manifestations hypercoagulation syndrome (thrombosis and thromboembolism) single patient not were observed.
Summary
Thus, in patients with AA showed increased activity of factor VIII and decreased levels of anti-thrombin. Whether these indicators markers hypercoagulation state, or is it a manifestation of compensatory functions, which prevent severe hemorrhagic complications in this category of patients. Research in this direction continues.
Keyword(s): Anemia, Hypercoagulation, Thrombocytopenia